Value of weight reduction in patients with cardiovascular disease

Current Treatment Options in Cardiovascular Medicine

Volumn 12, Issue 1, 2010, Pages 21-35

  Artham, Surya M ^a   Lavie, Carl J ^a   Milani, Richard V ^a   Ventura, Hector O ^a  

^a OCHSNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEPRAMONE; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; BUPROPION PLUS NALTREXONE; CONTRAVE; DEXFENFLURAMINE; FENFLURAMINE; FENFLURAMINE PLUS PHENTERMINE; FLUOXETINE; LORCASERIN; METRELEPTIN PLUS PRAMLINTIDE; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; QNEXA; RIMONABANT; SERTRALINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNCLASSIFIED DRUG; ZONISAMIDE;

ABDOMINAL CRAMP; ABNORMAL FECES; BARIATRIC SURGERY; BLOOD PRESSURE; BODY MASS; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EXERCISE; GASTRIC BANDING; GASTROPLASTY; HEADACHE; HEART RATE; HUMAN; LIFESTYLE MODIFICATION; NAUSEA; OBESITY; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEIZURE; SIDE EFFECT; STOMACH BYPASS; SUBSTANCE ABUSE; SUICIDE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 77649180090     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-009-0056-y     Document Type: Review

References (61)

1. CJ Lavie RV Milani HO Ventura 2009 Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss J Am Coll Cardiol 53 1925 1932 10.1016/j.jacc.2008.12.068 19460605 This is an excellent in-depth review of the latest literature on obesity, its CV impact, and the obesity paradox.
2. S Klein LE Burke GA Bray, et al. 2004 Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation Circulation 110 2952 2967 10.1161/01.CIR.0000145546.97738.1E 15509809 (Pubitemid 39473623)
3. P Poirier TD Giles GA Bray, et al. 2006 Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism Circulation 113 898 918 10.1161/CIRCULATIONAHA.106. 171016 16380542 (Pubitemid 43754312)
4. CJ Lavie AF Osman RV Milani, et al. 2003 Body composition and prognosis in chronic systolic heart failure: the obesity paradox Am J Cardiol 91 891 894 10.1016/S0002-9149(03)00031-6 12667583 (Pubitemid 36363743)
5. EE Calle MJ Thun JM Petrelli 1999 Body-mass index and mortality in a prospective cohort of US adults N Engl J Med 341 1097 1105 10.1056/ NEJM199910073411501 1:STN:280:DyaK1Mvis1GrsQ%3D%3D 10511607 (Pubitemid 29466221)
6. JE Manson SS Bassuk 2003 Obesity in the United States: a fresh look at its high toll JAMA 289 229 230 10.1001/jama.289.2.229 12517236 (Pubitemid 36068713)
7. SM Artham CJ Lavie RV Milani, et al. 2008 The obesity paradox: impact of obesity on the prevalence and prognosis of cardiovascular diseases Postgrad Med 120 34 41 10.3810/pgm.2008.07.1788 18654066
8. CJ Lavie RV Milani SM Artham, et al. 2009 The obesity paradox, weight loss, and coronary disease Am J Med 122 1106 1114 10.1016/j.amjmed.2009.06.006 1:CAS:528:DC%2BD1MXhsFagsrzL 19682667 This study proves the existence of the obesity paradox phenomenon in CHD patients.
9. CJ Lavie FH Messerli 1986 Cardiovascular adaptation to obesity and hypertension Chest 90 275 279 10.1378/chest.90.2.275 1:STN:280: DyaL283ntlGiuw%3D%3D 2942341
10. CJ Lavie RV Milani D Patel, et al. 2009 Disparate effects of obesity and left ventricular geometry on mortality in 8088 elderly patients with preserved systolic function Postgrad Med 121 119 125 10.3810/pgm.2009.05.2011 19491549
11. M Wei LW Gibbons JB Kampert, et al. 2000 Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes Ann Intern Med 132 605 611 1:STN:280:DC%2BD3c3hs1Cqsw%3D%3D 10766678
12. CJ Lavie RV Milani 2005 Cardiac rehabilitation and exercise training programs in metabolic syndrome and diabetes J Cardiopulm Rehabil 25 59 66 10.1097/00008483-200503000-00001 15818190
13. CJ Lavie RJ Thomas RW Squires, et al. 2009 Exercise training and cardiac rehabilitation in primary and secondary coronary prevention Mayo Clin Proc 84 373 383 10.4065/84.4.373 19339657 This paper nicely summarizes the importance of CRET in primary and secondary prevention of CVDs.
14. GW Lyerly X Sui CJ Lavie, et al. 2009 The association between cardiorespiratory fitness and risk of all-cause mortality among women with impaired fasting glucose or undiagnosed diabetes mellitus Mayo Clin Proc 84 780 786 10.4065/84.9.780 19720775 This study highlights the importance of having good CRF and its impact on all-cause mortality.
15. DB Allison R Zannolli MS Faith, et al. 1999 Weight loss increases and fat loss decreases all-cause mortality rates: results from two independent cohort studies Int J Obes Relat Metab Disord 23 603 611 10.1038/sj.ijo.0800875 1:STN:280:DyaK1MzjslSnsg%3D%3D 10411233
16. CJ Lavie RV Milani HO Ventura 2007 Obesity, heart disease, and favorable prognosis-truth or paradox? Am J Med 120 825 826 10.1016/j.amjmed.2007.06.023 17904447 (Pubitemid 47451306)
17. CJ Lavie RV Milani 2003 Obesity and cardiovascular disease: the hippocrates paradox? J Am Coll Cardiol 42 677 679 10.1016/S0735-1097(03)00784-8 12932600 (Pubitemid 37000184)
18. JW Anderson L Grant L Gotthelf, et al. 2006 Weight loss and long-term follow-up of severely obese individuals treated with an intense behavioral program Int J Obes 31 488 493 10.1038/sj.ijo.0803423
19. BJ Rolls EA Bell 2000 Dietary approaches to the treatment of obesity Med Clin North Am 84 401 418 10.1016/S0025-7125(05)70228-5 1:STN:280: DC%2BD3c3lsVWiuw%3D%3D 10793649
20. CJ Lavie A Morshedi-Meibodi RV Milani 2008 Impact of cardiac rehabilitation on coronary risk factors, inflammation, and the metabolic syndrome in obese coronary patients J Cardiometab Syndr 3 136 140 10.1111/j.1559-4572.2008.00002.x 18983328 This a detailed summary of the impact of CRET on CV risk factors, including MetS, in obese patients.
21. CJ Lavie R Milani 2009 Secondary coronary prevention in women: it starts with cardiac rehabilitation, exercise, and fitness J Womens Health (Larchmt) 18 1115 1117 10.1089/jwh.2009.1526
22. CJ Lavie RV Milani 2004 Benefits of cardiac rehabilitation in the elderly Chest 126 1010 1012 10.1378/chest.126.4.1010 15486351 (Pubitemid 39391219)
23. CJ Lavie RV Milani 1999 Effects of cardiac rehabilitation and exercise training on peak aerobic capacity and work efficiency in obese patients with coronary artery disease Am J Cardiol 15 1477 1480 10.1016/S0002-9149(99)00126-5 (Pubitemid 29228346)
24. CJ Lavie RV Milani 1997 Effects of cardiac rehabilitation, exercise training, and weight reduction on exercise capacity, coronary risk factors, behavioral characteristics, and quality of life in obese coronary patients Am J Cardiol 79 397 401 10.1016/S0002-9149(97)89239-9 1:STN:280:DyaK2s3gsVygsg%3D%3D 9052338
25. J Sierra-Johnson A Romero-Corral VK Somers, et al. 2008 Prognostic importance of weight loss in patients with coronary heart disease regardless of initial body mass index Eur Cardiovasc Prev Rehabil 15 336 340 10.1097/HJR.0b013e3282f48348
26. FJ Pashkow 1993 Issues in contemporary cardiac rehabilitation: a historical perspective J Am Coll Cardiol 21 822 834 1:STN:280: DyaK3s7ntFCrug%3D%3D 8436764
27. PA Ades PD Savage MJ Toth, et al. 2009 High-calorie-expenditure exercise: a new approach to cardiac rehabilitation for overweight coronary patients Circulation 119 2671 2678 10.1161/CIRCULATIONAHA.108.834184 19433757 This article highlights the triumph of intense high-calorie exercise over regular exercise. We expect these findings to bring forth changes in the exercise guidelines.
28. RW Jeffery A Drewnowski LH Epstein, et al. 2000 Long-term maintenance of weight loss: current status Health Psychol 19 5 16 10.1037/0278-6133.19.Suppl1.5 1:STN:280:DC%2BD3c7ntlWkug%3D%3D 10709944
29. ML Dansinger A Tabsioni JB Wong, et al. 2007 Meta-analysis: the effect of dietary counseling for weight loss Ann Intern Med 147 41 50 17606960
30. M Weintraub PR Sundaresan B Schuster, et al. 1992 Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise Clin Pharmacol Ther 51 595 601 1:STN:280:DyaK383ms1KltQ%3D%3D 1587073
31. Z Li M Maglione W Tu, et al. 2005 Meta-analysis: pharmacologic treatment of obesity Ann Intern Med 142 532 546 1:CAS:528:DC%2BD2MXjslCqsL8%3D 15809465
32. GA Bray GL Blackburn JM Ferguson, et al. 1999 Sibutramine produces dose-related weight loss Obes Res 7 189 198 1:CAS:528:DyaK1MXitFCjsbw%3D 10102256
33. G Fanghanel L Cortinas L Sanchez-Reyes, et al. 2000 A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity Int J Obes Relat Metab Disord 24 144 150 10.1038/sj.ijo.0801098 1:CAS:528:DC%2BD3cXhvFCisrs%3D 10702763
34. K Fujioka TB Seaton E Rowe, et al. 2000 Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus Diabetes Obes Metab 2 175 187 10.1046/j.1463-1326. 2000.00081.x 1:CAS:528:DC%2BD3cXltFKks78%3D 11220553 (Pubitemid 33072186)
35. WP James A Astrup N Finer, et al. 2000 Effect of sibutramine on weight maintenance after weight loss: a randomised trial Lancet 356 2119 2125 10.1016/S0140-6736(00)03491-7 1:CAS:528:DC%2BD3MXitlGhtQ%3D%3D 11191537 (Pubitemid 32047947)
36. HM Connolly JL Crary MD McGoon, et al. 1997 Valvular heart disease associated with fenfluramine-phentermine N Engl J Med 337 581 588 10.1056/NEJM199708283370901 1:CAS:528:DyaK2sXmtVGntLc%3D 9271479 (Pubitemid 27360757)
37. AM Heck JA Yanovski KA Calis 2000 Orlistat, a new lipase inhibitor for the management of obesity Pharmacotherapy 20 270 279 10.1592/phco.20.4.270.34882 1:CAS:528:DC%2BD3cXitFaksbw%3D 10730683
38. SZ Yanovski JA Yanovski 2002 Obesity N Engl J Med 346 591 602 10.1056/NEJMra012586 1:CAS:528:DC%2BD38XhsFOjsr4%3D 11856799 (Pubitemid 34438821)
39. Physicians' Desk Reference, edn 55. Montvale, NJ: Medical Economics; 2001.
40. FX Pi-Sunyer LJ Aronne HM Heshmati, et al. 2006 Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial JAMA 295 761 775 10.1001/jama.295.7.761 1:CAS:528:DC%2BD28XhsFOrs7g%3D 16478899 (Pubitemid 43244304)
41. SR Smith WA Prosser DJ Donahue, et al. 2008 Lorcaserin (APD356), a selective 5-HT2C agonist, reduces body weight in obese men and women Obesity 17 494 503 10.1038/oby.2008.537 19057523
42. Bio-Medicine. Available at http://www.bio-medicine.org. Accessed October 2009.
43. Medical News Today. Available at http://www.medicalnewstoday.com. Accessed October 2009.
44. Smith SR: Lorcaserin reduces body weight in obese and overweight subjects: Behavioral Modification and Lorcaserin for Overweight and Obesity Management, the BLOOM trial. Presented at the American Diabetes Association Scientific Sessions. New Orleans, LA; June 5-9, 2009.
45. Apovian C, Aronne L, Wyatt H, et al.: Results of the phase 3, 56-week, COR-II study: naltrexone SR/bupropion SR combination therapy led to significant and sustained weight loss in overweight and obese subjects. Presented at Obesity 2009. Washington, DC; October 27, 2009.
46. Smith SR, Aronne LJ, Apovian C, et al.: Pramlintide/metreleptin combination treatment for obesity: effect of dose and baseline BMI on magnitude of weight loss. Presented at Obesity 2009. Washington, DC; October 27, 2009.
47. S Eilat-Adar M Eldar U Goldbourt 2005 Association of intentional changes in body weight with coronary heart disease event rates in overweight subjects who have an additional coronary risk factor Am J Epidemiol 161 352 358 10.1093/aje/kwi045 15692079 (Pubitemid 40256207)
48. H Ashrafian CW le Roux A Darzi, et al. 2008 Effects of bariatric surgery on cardiovascular function Circulation 118 2091 2102 10.1161/CIRCULATIONAHA.107. 721027 19001033 This article summarizes the positive effects of gastric bypass surgery on CV health.
49. Consensus Development Conference Panel 1991 Gastrointestinal surgery for severe obesity Ann Intern Med 115 956 961
50. SH Jee JW Sull J Park, et al. 2006 Body-mass index and mortality in Korean men and women N Engl J Med 355 779 787 10.1056/NEJMoa054017 1:CAS:528:DC%2BD28Xos1Kmt7o%3D 16926276 (Pubitemid 44285583)
51. KR Fontaine DT Redden C Wang, et al. 2003 Years of life lost due to obesity JAMA 289 187 193 10.1001/jama.289.2.187 12517229 (Pubitemid 36068706)
52. TD Adams RE Gress SC Smith, et al. 2007 Long-term mortality after gastric bypass surgery N Engl J Med 357 753 761 10.1056/NEJMoa066603 1:CAS:528:DC%2BD2sXpsF2iu7k%3D 17715409 The authors show the mortality benefit from bariatric surgery in morbidly obese subjects.
53. R Steinbrook 2004 Surgery for severe obesity N Engl J Med 350 1075 1079 10.1056/NEJMp048029 1:CAS:528:DC%2BD2cXitV2qtbk%3D 15014179 (Pubitemid 38298986)
54. JA Tice L Karliner J Walsh, et al. 2008 Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures Am J Med 121 885 893 10.1016/j.amjmed.2008.05.036 18823860
55. L Sjostrom AK Lindroos M Peltonen, et al. 2004 Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery N Engl J Med 351 2683 2693 10.1056/NEJMoa035622 15616203 (Pubitemid 39665322)
56. Sjöström L, Narbro K, Sjöström DC, et al.: Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007, 357:741-752.
57. O'Riordan M: Bariatric surgery fails to reduce risk of MI long term. Available at http://www.theheart.org/article/1016585.do. Accessed November 2009.
58. GV Ramani C McCloskey RC Ramanathan, et al. 2008 Safety and efficacy of bariatric surgery in morbidly obese patients with severe systolic heart failure Clin Cardiol 31 516 520 10.1002/clc.20315 19006115 This article affirms the safety and efficacy of bariatric surgery in obese HF patients.
59. H Buchwald Y Avidor E Braunwald, et al. 2004 Bariatric surgery: a systematic review and meta-analysis JAMA 292 1724 1737 10.1001/jama.292.14.1724 1:CAS:528:DC%2BD2cXos1OjtLg%3D 15479938 (Pubitemid 39346675)
60. DG Carey GJ Pliego RL Raymond 2006 Body composition and metabolic changes following bariatric surgery: effects on fat mass, lean mass and basal metabolic rate: six months to one-year follow-up Obes Surg 16 1602 1608 10.1381/096089206779319347 17217636 (Pubitemid 46032813)
61. OJ Rider JM Francis MK Ali, et al. 2009 Beneficial cardiovascular effects of bariatric surgical and dietary weight loss in obesity J Am Coll Cardiol 54 718 726 10.1016/j.jacc.2009.02.086 19679250